Ifosfamide, Cisplatin or Carboplatin, and Etoposide （ICE）-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas  

作　　者：Ping Zhou Peng Liu Sheng-Yu Zhou Xiao-Hui He Xiao-Hong Han Yan Qin Sheng Yang Chang-Gong Zhang Lin Gui Jia-Rui Yao Li-Ya Zhao Shu-Xiang Zhang Yan Sun Yuan-KaiShi 

机构地区：[1]Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China

出　　处：《Chinese Medical Journal》2015年第18期2498-2504,共7页中华医学杂志（英文版）

摘　　要：Background： High-dose chemotherapy followed by autologous stem cell transplantation （ASCT） is a promising approach tbr lymphomas. This study aimed to evaluate the effect of ifosfamide, cisplatin or carboplatin, and etoposide （ICE）-based regimen as a mobilization regimen on relapsed, refractory, or high-risk aggressive lymphoma. Methods： From June 2001 to May 2013, patients with lymphomas who mobilized by ICE-based regimen for ASCT were analyzed in this retrospective study. The results of the autologous peripheral blood stem cells collection, toxicity, engraftment after ICE-based mobilization regimen were analyzed in this study. Furthermore, risk factors for overall survival （OS） and progression free survival （PFS） were evaluated by univariate analysis. Results： The stem cells were mobilized using ICE-based regimen plus rituximab or ICE-based regimen alone in 12 patients and 54 patients, respectively. The results of stem cell mobilization were excellent. Ninety-seven percentages of the patients had the stein cell collection of at least 2.0 ×10^6, CD34^＋ cells/kg and 68% had at least 5 × 10^6, CD34^＋ cells/kg. Fifty-eight percentage of the patients experienced Grade 4 neutropenia, 20% developed febrile neutropenia, and only 12% had Grade 4 thrombocytopenia. At a median follow-up of 63.8 months, the 5-year PFS and OS were 64.4% and 75.3%, respectively. Conclusion： ICE is a powerful regimen for stem cell mobilization in patients with lymphomas.Background： High-dose chemotherapy followed by autologous stem cell transplantation （ASCT） is a promising approach tbr lymphomas. This study aimed to evaluate the effect of ifosfamide, cisplatin or carboplatin, and etoposide （ICE）-based regimen as a mobilization regimen on relapsed, refractory, or high-risk aggressive lymphoma. Methods： From June 2001 to May 2013, patients with lymphomas who mobilized by ICE-based regimen for ASCT were analyzed in this retrospective study. The results of the autologous peripheral blood stem cells collection, toxicity, engraftment after ICE-based mobilization regimen were analyzed in this study. Furthermore, risk factors for overall survival （OS） and progression free survival （PFS） were evaluated by univariate analysis. Results： The stem cells were mobilized using ICE-based regimen plus rituximab or ICE-based regimen alone in 12 patients and 54 patients, respectively. The results of stem cell mobilization were excellent. Ninety-seven percentages of the patients had the stein cell collection of at least 2.0 ×10^6, CD34^＋ cells/kg and 68% had at least 5 × 10^6, CD34^＋ cells/kg. Fifty-eight percentage of the patients experienced Grade 4 neutropenia, 20% developed febrile neutropenia, and only 12% had Grade 4 thrombocytopenia. At a median follow-up of 63.8 months, the 5-year PFS and OS were 64.4% and 75.3%, respectively. Conclusion： ICE is a powerful regimen for stem cell mobilization in patients with lymphomas.

关 键 词：ICE Mobilization： Rituximab Stem Cell Transplantation 

分 类 号：TQ463.26[化学工程—制药化工] Q25[生物学—细胞生物学]